Market Overview

UPDATE: Jefferies & Company Reiterates Underperform Rating, Raises PT on Eli Lilly & Co.

Share:
Related LLY
6 Biggest Price Target Changes For Thursday
Delta, United, Eli Lilly, General Electric: Fast Money Picks For July 13
Fed, FANGs, Autos, Defense, Eateries On Deck: Investing Action Plan (Investor's Business Daily)

In a report published Wednesday, Jefferies & Company reiterated its Underperform rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $36.00 to $43.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Eli Lilly & Co. closed on Tuesday at $52.80.

Latest Ratings for LLY

DateFirmActionFromTo
Jul 2017Deutsche BankMaintainsBuy
Jul 2017JefferiesMaintainsBuy
Apr 2017Argus ResearchDowngradesBuyHold

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

View Comments and Join the Discussion!